Hemispherx Biopharma, Bioclones join forces on novel therapeutic cancer vaccine
On June 25, 2014, Bioclones and Hemispherx concluded strategic discussions in Johannesburg with three principle goals; 1) initiating studies utilizing Ampligen as a potential adjuvant enhancement of Bioclones’
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.